Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Mirum succeeds in rare liver disease trial; First Tracks delivers in celiac

Mirum Pharmaceuticals’ late-stage win in ultra-rare liver diseases: The company’s ileal bile acid transporter inhibitor Livmarli significantly reduced cholestatic pruritus versus placebo in patients with cholestatic liver diseases, including biliary atresia ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Monday 12 October →